An Analytical Reference Standard
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

(±)-CP 55,940

Item No. 13241

Restricted Product (Schedule I)
Product Insert (PDF)GC-MS (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
rel-5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol
CAS Number
83003-12-7
Molecular Formula
C24H40O3
Formula Weight
376.6
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlEthanol:PBS (pH 7.2) (1:3): 0.25 mg/ml
λmax
278 nm
SMILES
O[C@H]1C[C@@H](C2=CC=C(C(C)(C)CCCCCC)C=C2O)[C@H](CCCO)CC1
InChi Code
InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1
InChi Key
YNZFFALZMRAPHQ-SYYKKAFVSA-N
Regulatory Information
DEA Schedule
I
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $90

    Add

    5 mg

    $396

    Add
    Cayman Chemical
    Cayman Spectral Library

    Our free, searchable, GC-MS spectral database contains 70eV EI mass spectral data of 2,000+ of Cayman’s forensic drug standards.

    DOWNLOAD THE DATABASE
    Product Description

    (±)-CP 55,940 (Item No. 13241) is an analytical reference standard categorized as a synthetic cannabinoid.1 It induces self-administration of morphine in rats. This product is intended for research and forensic applications.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Biscaia, M., Fernández, B., Higuera-Matas, A., et al. Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 54(5), 863-873 (2008).

    Product Citations

    Patel, M., Ganeshan, D., Horgan, I., et al. AB-MDMSBA—not a synthetic cannabinoid receptor agonist. Pharmacol. Res. Perspect. 14:e70278 (2026).

    Mercier, G., Mohamed, K.A., Zagzoog, A., et al. In vitro pharmacological activity of twenty-eight synthetic cannabinoid receptor agonists at the type 1 and 2 cannabinoid receptors. Neurochem. Int. 190, 106039 (2025).

    Kundu, D., Franchini, L., Hasdemir, H.S., et al. Distinct interactions of cannabinol and its cytochrome P450-generated metabolites with receptors and sensory neurons. J. Med. Chem. 68(13), 13935-13953 (2025).

    Pulver, B., Schönberger, T., Weigel, D., et al. Structure elucidation of the novel synthetic cannabinoid Cumyl-Tosyl-Indazole-3-Carboxamide (Cumyl-TsINACA) found in illicit products in Germany. Drug Test. Anal. 14(8), 1387-1406 (2022).

    Grafinger, K.E., Vandeputte, M.M., Cannaert, A., et al. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Drug Test. Anal. 13(7), 1412-1429 (2021).

    Li, A.-L., Lin, X., Dhopeshwarkar, A.S., et al. The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal. Mol. Pharmacol. 95(2), 155-168 (2019).

    Sachdev, S., Vemuri, K., Banister, S.D., et al. In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. (2019).

    Longworth, M., Reekie, T.A., Blakey, K., et al. New‑generation azaindole‑adamantyl‑derived synthetic cannabinoids. Forensic Toxicol. 37, 350-365 (2019).

    Ciolino, L.A. Quantitation of synthetic cannabinoids in plant materials using high performance liquid chromatography with UV detection (validated method). J. Forensic Sci. 60(5), 1171-1181 (2015).

    Ribeiro, R., Wen, J., Li, S., et al. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 100-101, (2013).